There is an unmet medical need to improve the treatment of patients with established atherosclerotic cardiovascular disease (ASCVD), especially those with chronic kidney disease (CKD), and thereby reduce their risk of cardiovascular (CV) events. Inflammation is an additional important risk factor to address in patients with ASCVD at high risk of major adverse cardiovascular events (MACE).
The primary objective of this study is to demonstrate the superiority of the study drug given once monthly in reducing the risk of major adverse cardiovascular events when compared to placebo, both added to standard of care, in participants with established ASCVD, CKD and systemic inflammation. Standard of care treatment will be maintained throughout the study for all participants.
Qualified participants will: